These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10423924)

  • 1. Use of granulocyte colony-stimulating factor (G-CSF) in clinical practice in Fukuoka City area in Japan.
    Tamura K
    Fukuoka Igaku Zasshi; 1999 Jun; 90(6):279-85. PubMed ID: 10423924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
    Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
    Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
    Bennett CL; Smith TJ; Weeks JC; Bredt AB; Feinglass J; Fetting JH; Hillner BE; Somerfield MR; Winn RJ
    J Clin Oncol; 1996 Sep; 14(9):2511-20. PubMed ID: 8823330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytokines in cancer chemotherapy: present state and problems in use of G- and GM-CSF for solid tumors in Japan].
    Ogawara M
    Gan To Kagaku Ryoho; 1998 Jan; 25(2):164-70. PubMed ID: 9474924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evidence-based management of neutropenia and fever].
    Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases.
    Kavgaci H; Ozdemir F; Aydin F; Yavuz A; Yavuz M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):475-9. PubMed ID: 12636092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
    Shochat E; Rom-Kedar V
    Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
    Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
    J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.
    Rajan SS; Stearns SC; Lyman GH; Carpenter WR
    Breast Cancer Res Treat; 2011 Nov; 130(1):255-66. PubMed ID: 21584667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.